Physician profile
Melissa Chan
NPI 1922681626
$6,258.23
in general payments reported to CMS, 2019-2025
18 companies · $3,570 in 2025
The $3,570 reported for 2025 was more than what 97% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $2,688 · 2025: $3,570.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,258.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,133.58 | 2024-2025 | Repatha, Evenity, Otezla |
| Astrazeneca Pharmaceuticals LP | $883.88 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $837.82 | 2024-2025 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $578.52 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $465.48 | 2024-2025 | Ozempic, Wegovy |
| Phathom Pharmaceuticals, INC. | $430.56 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $428.02 | 2024-2025 | Rezdiffra |
| Abbvie INC. | $328.78 | 2024-2025 | |
| Gilead Sciences, INC. | $279.90 | 2024-2025 | Livdelzi, Vemlidy |
| Bayer Healthcare Pharmaceuticals INC. | $229.27 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $164.58 | 2025 | Zoryve |
| Exact Sciences Corporation | $153.33 | 2024-2025 | Cologuard Collection Kit |
| Mallinckrodt Hospital Products INC. | $142.46 | 2025 | Acthar |
| Shield Therapeutics INC | $83.58 | 2024-2025 | |
| Pfizer INC. | $47.73 | 2025 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $27.28 | 2025 | Fluad, Flucelvax |
| Merck Sharp & Dohme LLC | $22.73 | 2025 | Capvaxive, Gardasil 9 |
| Ardelyx, INC. | $20.73 | 2025 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Chan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.